Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 94
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | ||
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | ||
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) | ||
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | ||
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | ||
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | ||
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | ||
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | ||
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | ||
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | ||
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | ||
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | ||
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | ||
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | ||
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | ||
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | ||
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | ||
| NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | ||
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | ||
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes | ||
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | ||
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | ||
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | ||
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | ||
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | ||
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | ||
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | ||
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | ||
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | ||
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | ||
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer | ||
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | ||
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | ||
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | ||
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) | ||
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | ||
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | ||
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | ||
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | ||
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | ||
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | ||
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | ||
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | ||
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | ||
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | ||
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | ||
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | ||
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease |
